A tool for measuring radiation doses from alpha-particle cancer treatments
Official title: Cloud/Subscription based, Customer-Responsive Dosimetry Tool for alpha-Particle Emitters
Funded at Radiopharmaceutical Imaging and Dosimetry, LLC · NIH-10921546 · Data updated 2026-11-12
This study is creating a new online tool to help doctors better measure the radiation doses used in cancer treatments with alpha particles, making sure they target cancer cells effectively while protecting healthy tissues, so patients can receive safer and more effective care.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Radiopharmaceutical Imaging and Dosimetry, LLC NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | August 5, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $898,497 |
| NIH project number | 1R44CA291420-01 |
| Project ID | NIH-10921546 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients receiving radiopharmaceutical therapy that utilizes alpha-particle emitters.
✕Less likely to help
Patients who are not undergoing radiopharmaceutical therapy or those receiving treatments that do not involve alpha-particle emitters may not benefit from this research.
What this research studies
This research focuses on developing a cloud-based dosimetry tool specifically designed for alpha-particle emitters used in cancer therapy. It aims to improve the evaluation of radiation doses delivered to cancer cells while minimizing damage to healthy tissues. The methodology involves a novel approach that translates macroscopic activity measurements into detailed microscopic activity distributions, which is crucial for assessing treatment efficacy and normal tissue toxicity. By enhancing the accuracy of dose calculations, this tool could significantly improve treatment planning for patients undergoing radiopharmaceutical therapy.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer cancer treatments by optimizing radiation delivery to tumors while protecting healthy tissues.
How similar studies have gone: Previous research has shown promise in developing dosimetry tools for other types of radiation therapies, but this specific approach for alpha-particle emitters is relatively novel.
Where this research is happening
-
Radiopharmaceutical Imaging and Dosimetry, LLC
Baltimore, United States Active
Researchers
- Principal investigator: Ghaly, Michael — Radiopharmaceutical Imaging and Dosimetry, LLC
- Study coordinator: Ghaly, Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.